Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRIAN CONFREY MAZZARELLA

Allopathic & Osteopathic Physicians Urology

NPI
1417265851
CMS profile
1390616
Location
LAKEWAY, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$394,196.79

269 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
NeoTract Inc. $393,958.80 259
Boston Scientific Corporation $80.47 3
PROCEPT BioRobotics Corporation $80.27 3
180 Medical, Inc. $22.34 1
Allergan Inc. $20.89 1
Endo Pharmaceuticals Inc. $18.86 1
PFIZER INC. $15.16 1

Page 4 of 6; records 151–200 of 269 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRIAN CONFREY MAZZARELLA

NPI 1417265851 · CMS profile ID 1390616

Allopathic & Osteopathic Physicians / Urology

LAKEWAY, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 6; records 151–200 of 269 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1417265851?year=2019&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRIAN CONFREY MAZZARELLA, NPI 1417265851, CMS profile ID 1390616. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 6; records 151–200 of 269 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1417265851?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). BRIAN CONFREY MAZZARELLA, NPI 1417265851, CMS profile ID 1390616. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 6; records 151–200 of 269 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1417265851?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
BRIAN CONFREY MAZZARELLA, NPI 1417265851, CMS profile ID 1390616, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 6; records 151–200 of 269 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1417265851?year=2019&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

269 matching records · $394,196.79 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 269 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 269.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
NeoTract Inc. $1,800.0006/11/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688543223 CMS
NeoTract Inc. $108.2806/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688527991 CMS
NeoTract Inc. $3.3606/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688527995 CMS
NeoTract Inc. $4.6706/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688527999 CMS
NeoTract Inc. $16.0906/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688528007 CMS
NeoTract Inc. $244.5306/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688528037 CMS
NeoTract Inc. $16.2306/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688550553 CMS
NeoTract Inc. $115.2006/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688550549 CMS
NeoTract Inc. $2.6506/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688531399 CMS
NeoTract Inc. $43.8906/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688531401 CMS
NeoTract Inc. $16.6706/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688531403 CMS
NeoTract Inc. $2.2005/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688528161 CMS
NeoTract Inc. $55.0605/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688550551 CMS
NeoTract Inc. $9,800.0005/29/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688543207 CMS
NeoTract Inc. $4,100.0005/29/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688543209 CMS
NeoTract Inc. $24,800.0005/29/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688543211 CMS
NeoTract Inc. $652.1105/29/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688543213 CMS
NeoTract Inc. $26.6905/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688550529 CMS
NeoTract Inc. $111.2605/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688528003 CMS
NeoTract Inc. $40.0105/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688550537 CMS
NeoTract Inc. $136.5505/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688528131 CMS
NeoTract Inc. $6,700.0005/15/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688543203 CMS
NeoTract Inc. $2,900.0005/15/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688543205 CMS
NeoTract Inc. $164.6105/14/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688527833 CMS
NeoTract Inc. $540.5305/14/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688527841 CMS
NeoTract Inc. $135.4705/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688550555 CMS
NeoTract Inc. $42.3405/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688550531 CMS
NeoTract Inc. $122.8305/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688543379 CMS
NeoTract Inc. $28.7405/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688528205 CMS
NeoTract Inc. $127.0505/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688543375 CMS
PROCEPT BioRobotics Corporation $42.0805/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705883747 CMS
NeoTract Inc. $125.7605/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688528191 CMS
NeoTract Inc. $24.9704/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688528017 CMS
NeoTract Inc. $7.7904/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688528177 CMS
NeoTract Inc. $16.9704/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688528179 CMS
NeoTract Inc. $10.2504/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688528257 CMS
NeoTract Inc. $137.2304/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688528259 CMS
NeoTract Inc. $3,700.0004/30/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688543197 CMS
NeoTract Inc. $2,000.0004/30/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688543199 CMS
NeoTract Inc. $4,400.0004/30/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688543201 CMS
NeoTract Inc. $120.0704/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688528069 CMS
NeoTract Inc. $37.3804/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688550543 CMS
NeoTract Inc. $100.6204/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688550547 CMS
NeoTract Inc. $59.0904/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688528181 CMS
NeoTract Inc. $107.5204/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688550559 CMS
NeoTract Inc. $137.0304/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688527983 CMS
NeoTract Inc. $29.8504/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688528035 CMS
NeoTract Inc. $24.6504/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688528217 CMS
NeoTract Inc. $143.4804/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688527989 CMS
NeoTract Inc. $29.7804/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688550557 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $394,196.79 269
PY2020 $401,986.68 441
PY2021 $216,489.66 183
PY2022 $87,018.84 78
PY2023 $59,360.30 61
PY2024 $6,162.85 20
PY2025 $8,747.92 37

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,368,064.91 131
PY2024 Principal investigator $1,334,006.10 79
PY2023 Principal investigator $50,424.52 18
PY2022 Principal investigator $114,657.35 20
PY2021 Principal investigator $307,941.17 17
PY2020 Principal investigator $24,628.88 1
PY2019 Principal investigator $80,124.32 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

131 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $35,000.00 12/31/2025 Non-covered Recipient Entity
Urology Austin
A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigators Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge No dispute reported 06/30/2026 1235992285
Principal investigator 1 Janssen Research & Development, LLC $1,538.00 12/29/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175335081
Principal investigator 1 Janssen Research & Development, LLC $6,727.00 12/29/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175335103
Principal investigator 1 Janssen Research & Development, LLC $48,091.00 12/29/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175335112
Principal investigator 1 Janssen Research & Development, LLC $21.00 12/26/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175334858
Principal investigator 1 Janssen Research & Development, LLC $828.00 12/26/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175335145
Principal investigator 1 Janssen Research & Development, LLC $990.00 12/26/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations No dispute reported 06/30/2026 1175335306
Principal investigator 1 Janssen Research & Development, LLC $6,808.00 12/25/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175334730
Principal investigator 1 Janssen Research & Development, LLC $621.00 12/25/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175334818
Principal investigator 1 AstraZeneca Pharmaceuticals LP $6,989.70 12/23/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
a phase 3b,open label,single arm,multi center,US study of bacillus calmette guerin bcg administered in combination with durvalumab in adult bcg naive,high risk non muscle invasive bladder cancer participants patapsco No dispute reported 06/30/2026 1185539481
Principal investigator 1 Janssen Research & Development, LLC $73,865.00 12/23/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants with High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Gurin (BCG) No dispute reported 06/30/2026 1175334781
Principal investigator 1 Janssen Research & Development, LLC $5,779.00 12/22/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations No dispute reported 06/30/2026 1175334827
Principal investigator 1 Janssen Research & Development, LLC $4,558.00 12/18/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175334977
Principal investigator 1 Janssen Research & Development, LLC $2,202.00 12/15/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175335007
Principal investigator 1 Janssen Research & Development, LLC $19,275.00 12/15/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175335056
Principal investigator 1 Janssen Research & Development, LLC $9,114.00 11/24/2025 Non-covered Recipient Entity
Uro Austin Pllc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175277310
Principal investigator 1 Janssen Research & Development, LLC $1,200.00 11/24/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations No dispute reported 06/30/2026 1175335000
Principal investigator 1 Janssen Research & Development, LLC $7,499.00 11/07/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175335249
Principal investigator 1 Janssen Research & Development, LLC $200.00 11/07/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175335298
Principal investigator 1 Sumitomo Pharma America, Inc. $43,627.60 11/05/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176655016
Principal investigator 1 Janssen Research & Development, LLC $6,593.00 11/03/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175334971
Principal investigator 1 Janssen Research & Development, LLC $1,559.00 10/30/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients No dispute reported 06/30/2026 1175334738
Principal investigator 1 Janssen Research & Development, LLC $800.00 10/23/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations No dispute reported 06/30/2026 1175335217
Principal investigator 1 Janssen Research & Development, LLC $500.00 10/13/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175334907
Principal investigator 1 Janssen Research & Development, LLC $133.00 10/06/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations No dispute reported 06/30/2026 1175334798
Principal investigator 1 Janssen Research & Development, LLC $800.00 10/06/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175335161
Principal investigator 1 Janssen Research & Development, LLC $13,372.00 10/03/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175335212
Principal investigator 1 Janssen Research & Development, LLC $3,444.00 10/02/2025 Non-covered Recipient Entity
Uro Austin Pllc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175277317
Principal investigator 1 Janssen Research & Development, LLC $27,319.00 10/02/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175335095
Principal investigator 1 Janssen Research & Development, LLC $32,500.00 09/29/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175335271
Principal investigator 1 Janssen Research & Development, LLC $4,959.00 09/17/2025 Non-covered Recipient Entity
Uro Austin Pllc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175276899
Principal investigator 1 Novartis Pharmaceuticals Corporation $211.29 09/15/2025 Non-covered Recipient Entity
UROLOGY AUSTIN LAKEWAY
A Phase II, Open-label, Multi-Center, Randomized Study Comparing the Combination of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) and Androgen Receptor Pathway Inhibitor (ARPI) vs. Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in First-line Treatment No dispute reported 06/30/2026 1190304561
Principal investigator 1 Janssen Research & Development, LLC $21,244.00 09/08/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175335187
Principal investigator 1 Janssen Research & Development, LLC $10,739.00 09/08/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175335204
Principal investigator 1 Arrow International, Inc. $1,841.50 08/29/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
INVESTIGATING MEDICATION VERSUS PROSTATIC URETHRAL LIFT:ASSESSMENT AND COMPARISON OF THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA No dispute reported 06/30/2026 1242470441
Principal investigator 1 Janssen Research & Development, LLC $1,722.00 08/28/2025 Non-covered Recipient Entity
Uro Austin Pllc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175277496
Principal investigator 1 Janssen Research & Development, LLC $600.00 08/28/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175334888
Principal investigator 1 Janssen Research & Development, LLC $23,255.00 08/11/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175334882
Principal investigator 1 Sumitomo Pharma America, Inc. $3,677.40 08/01/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176641703
Principal investigator 1 Janssen Research & Development, LLC $4,501.00 07/31/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175334849
Principal investigator 1 Janssen Research & Development, LLC $3,444.00 07/28/2025 Non-covered Recipient Entity
Uro Austin Pllc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175275415
Principal investigator 1 Janssen Research & Development, LLC $1,957.00 07/28/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175334765
Principal investigator 1 Janssen Research & Development, LLC $14,168.00 07/28/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175334942
Principal investigator 1 Janssen Research & Development, LLC $19,905.00 07/28/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175335257
Principal investigator 1 Janssen Research & Development, LLC $1,518.00 07/21/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175334991
Principal investigator 1 Janssen Research & Development, LLC $2,897.00 07/18/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175334949
Principal investigator 1 Janssen Research & Development, LLC $1,393.00 07/17/2025 Non-covered Recipient Entity
Uro Austin Pllc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175275718
Principal investigator 1 Janssen Research & Development, LLC $1,494.00 07/14/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175335130
Principal investigator 1 Arrow International, Inc. $1,050.00 07/11/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
INVESTIGATING MEDICATION VERSUS PROSTATIC URETHRAL LIFT:ASSESSMENT AND COMPARISON OF THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA No dispute reported 06/30/2026 1242470413
Principal investigator 1 Sumitomo Pharma America, Inc. $1,225.80 07/09/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176640296
Principal investigator 1 Janssen Research & Development, LLC $29,602.00 07/07/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175335066
Principal investigator 1 Janssen Research & Development, LLC $9,050.00 07/04/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175334771
Principal investigator 1 Janssen Research & Development, LLC $14,246.00 07/04/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175335122
Principal investigator 1 Janssen Research & Development, LLC $35,526.00 06/30/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175334897
Principal investigator 1 Arrow International, Inc. $4,902.20 06/27/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
INVESTIGATING MEDICATION VERSUS PROSTATIC URETHRAL LIFT:ASSESSMENT AND COMPARISON OF THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA No dispute reported 06/30/2026 1242470409
Principal investigator 1 Janssen Research & Development, LLC $1,957.00 06/27/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175334756
Principal investigator 1 Janssen Research & Development, LLC $4,413.00 06/25/2025 Non-covered Recipient Entity
Uro Austin Pllc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175275213
Principal investigator 1 Janssen Research & Development, LLC $87.00 06/11/2025 Non-covered Recipient Entity
Uro Austin Pllc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175277038
Principal investigator 1 Janssen Research & Development, LLC $6,135.00 06/09/2025 Non-covered Recipient Entity
Uro Austin Pllc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175276648
Principal investigator 1 Janssen Research & Development, LLC $29,075.00 06/06/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Ca No dispute reported 06/30/2026 1175335169
Principal investigator 1 Janssen Research & Development, LLC $8,926.00 06/02/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-m No dispute reported 06/30/2026 1175334836
Principal investigator 1 Janssen Research & Development, LLC $1,518.00 06/02/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175335178
Principal investigator 1 Janssen Research & Development, LLC $2,164.00 05/30/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175335323
Principal investigator 1 Arrow International, Inc. $1,727.50 05/29/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
INVESTIGATING MEDICATION VERSUS PROSTATIC URETHRAL LIFT:ASSESSMENT AND COMPARISON OF THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA No dispute reported 06/30/2026 1242470403
Principal investigator 1 Arrow International, Inc. $615.00 05/28/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
INVESTIGATING MEDICATION VERSUS PROSTATIC URETHRAL LIFT:ASSESSMENT AND COMPARISON OF THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA No dispute reported 06/30/2026 1242470399
Principal investigator 1 Arrow International, Inc. $8,351.13 05/28/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
INVESTIGATING MEDICATION VERSUS PROSTATIC URETHRAL LIFT:ASSESSMENT AND COMPARISON OF THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA No dispute reported 06/30/2026 1242470401
Principal investigator 1 Janssen Research & Development, LLC $28.00 05/23/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175334788
Principal investigator 1 Janssen Research & Development, LLC $1,349.00 05/23/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175335035
Principal investigator 1 Janssen Research & Development, LLC $4,459.00 05/22/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175335232
Principal investigator 1 Janssen Research & Development, LLC $19,757.00 05/19/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175335279
Principal investigator 1 Janssen Research & Development, LLC $23,920.00 05/12/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175335073
Principal investigator 1 Janssen Research & Development, LLC $6,009.00 05/08/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175335334
Principal investigator 1 Sumitomo Pharma America, Inc. $3,707.40 05/07/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176634132
Principal investigator 1 Sumitomo Pharma America, Inc. $60.00 05/07/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176634136
Principal investigator 1 Janssen Research & Development, LLC $36,527.00 04/28/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175334812
Principal investigator 1 Janssen Research & Development, LLC $17,188.00 04/25/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175334747
Principal investigator 1 Janssen Research & Development, LLC $3,112.00 04/24/2025 Non-covered Recipient Entity
Uro Austin Pllc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175275726
Principal investigator 1 Janssen Research & Development, LLC $3,754.00 04/24/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175334957
Principal investigator 1 Janssen Research & Development, LLC $400.00 04/16/2025 Non-covered Recipient Entity
Uro Austin Pllc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175276308
Principal investigator 1 Sumitomo Pharma America, Inc. $2,451.60 04/09/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176632584
Principal investigator 1 Sumitomo Pharma America, Inc. $500.00 04/09/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176632587
Principal investigator 1 Sumitomo Pharma America, Inc. $2,451.60 04/09/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176632592
Principal investigator 1 Janssen Research & Development, LLC $16,273.00 04/07/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175334872
Principal investigator 1 Janssen Research & Development, LLC $36,141.00 04/07/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175334914
Principal investigator 1 Teleflex Medical Incorporated $1,322.50 03/31/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
INVESTIGATING MEDICATION VERSUS PROSTATIC URETHRAL LIFT:ASSESSMENT AND COMPARISON OF THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA No dispute reported 06/30/2026 1242470532
Principal investigator 1 Janssen Research & Development, LLC $837.00 03/27/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175335025
Principal investigator 1 Janssen Research & Development, LLC $986.00 03/27/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175335042
Principal investigator 1 Janssen Research & Development, LLC $1,104.00 03/24/2025 Non-covered Recipient Entity
Uro Austin Pllc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175275711
Principal investigator 1 Janssen Research & Development, LLC $652.00 03/24/2025 Non-covered Recipient Entity
Uro Austin Pllc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175276802
Principal investigator 1 Janssen Research & Development, LLC $1,220.00 03/21/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175334966
Principal investigator 1 Janssen Research & Development, LLC $763.00 03/18/2025 Non-covered Recipient Entity
Uro Austin Pllc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175291900
Principal investigator 1 Janssen Research & Development, LLC $5,075.00 03/17/2025 Non-covered Recipient Entity
Uro Austin Pllc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175291892
Principal investigator 1 Calyxo, Inc. $2,500.00 03/14/2025 Non-covered Recipient Entity
Urology Austin, PLLC
ASPIRE No dispute reported 06/30/2026 1245038295
Principal investigator 1 Janssen Research & Development, LLC $2,464.00 03/14/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175334983
Principal investigator 1 Janssen Research & Development, LLC $1,370.00 03/13/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175335241
Principal investigator 1 Janssen Research & Development, LLC $400.00 03/10/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175334928
Principal investigator 1 Janssen Research & Development, LLC $17,413.00 03/10/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175335049
Principal investigator 1 Janssen Research & Development, LLC $3,165.00 03/10/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175335195
Principal investigator 1 Janssen Research & Development, LLC $1,774.00 03/10/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175335224
Principal investigator 1 Janssen Research & Development, LLC $28,786.00 03/10/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175335293
Principal investigator 1 Janssen Research & Development, LLC $400.00 03/03/2025 Non-covered Recipient Entity
Uro Austin Pllc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175276322
Principal investigator 1 Janssen Research & Development, LLC $2,164.00 03/03/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175334865
Principal investigator 1 Janssen Research & Development, LLC $19,404.00 02/28/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175335088
Principal investigator 1 Teleflex LLC $20,300.00 02/28/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
RANDOMIZED TRIAL OF BARRIGEL TO INCREASE DISTANCE BETWEEN THE RECTUM AND PROSTATE BED TO DECREASE RECTAL DOSE IN PATIENTS RECEIVING MODERATELY HYPOFRACTIONATED RADIATION THERAPY WHO HAVE HAD RECURRENCE OF PROSTATE CANCER AFTER PROSTATECTOMY No dispute reported 06/30/2026 1242432080
Principal investigator 1 Janssen Research & Development, LLC $8,187.00 02/21/2025 Non-covered Recipient Entity
Uro Austin Pllc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175276152
Principal investigator 1 Janssen Research & Development, LLC $4,159.00 02/14/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175334805
Principal investigator 1 Janssen Research & Development, LLC $57,702.00 02/10/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175335263
Principal investigator 1 Teleflex Medical Incorporated $135.00 02/10/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
INVESTIGATING MEDICATION VERSUS PROSTATIC URETHRAL LIFT:ASSESSMENT AND COMPARISON OF THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA No dispute reported 06/30/2026 1242470530
Principal investigator 1 Janssen Research & Development, LLC $3,914.00 02/03/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175334842
Principal investigator 1 Janssen Research & Development, LLC $21,035.00 02/03/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175335016
Principal investigator 1 AstraZeneca Pharmaceuticals LP $236,229.33 01/29/2025 Non-covered Recipient Entity
UROLOGY AUSTIN CORPORATE
a phase 3b,open label,single arm,multi center,US study of bacillus calmette guerin bcg administered in combination with durvalumab in adult bcg naive,high risk non muscle invasive bladder cancer participants patapsco No dispute reported 06/30/2026 1185539483
Principal investigator 1 Janssen Research & Development, LLC $9,325.00 01/28/2025 Non-covered Recipient Entity
Uro Austin Pllc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175275481
Principal investigator 1 Janssen Research & Development, LLC $19,986.00 01/27/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175335153
Principal investigator 1 Janssen Research & Development, LLC $849.00 01/24/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175335135
Principal investigator 1 Janssen Research & Development, LLC $4,525.00 01/24/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175335316
Principal investigator 1 Janssen Research & Development, LLC $326.00 01/22/2025 Non-covered Recipient Entity
Uro Austin Pllc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175275497
Principal investigator 1 Janssen Research & Development, LLC $772.00 01/22/2025 Non-covered Recipient Entity
Uro Austin Pllc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175276495
Principal investigator 1 Teleflex Medical Incorporated $985.00 01/07/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
INVESTIGATING MEDICATION VERSUS PROSTATIC URETHRAL LIFT:ASSESSMENT AND COMPARISON OF THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA No dispute reported 06/30/2026 1242470526
Principal investigator 1 Teleflex Medical Incorporated $975.00 01/07/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
INVESTIGATING MEDICATION VERSUS PROSTATIC URETHRAL LIFT:ASSESSMENT AND COMPARISON OF THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA No dispute reported 06/30/2026 1242470528
Principal investigator 1 Arrow International, Inc. $1,052.50 01/06/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
INVESTIGATING MEDICATION VERSUS PROSTATIC URETHRAL LIFT:ASSESSMENT AND COMPARISON OF THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA No dispute reported 06/30/2026 1242470355
Principal investigator 1 Teleflex Medical Incorporated $985.00 01/06/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
INVESTIGATING MEDICATION VERSUS PROSTATIC URETHRAL LIFT:ASSESSMENT AND COMPARISON OF THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA No dispute reported 06/30/2026 1242470506
Principal investigator 1 Teleflex Medical Incorporated $4,265.00 01/06/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
INVESTIGATING MEDICATION VERSUS PROSTATIC URETHRAL LIFT:ASSESSMENT AND COMPARISON OF THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA No dispute reported 06/30/2026 1242470508
Principal investigator 1 Teleflex Medical Incorporated $615.00 01/06/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
INVESTIGATING MEDICATION VERSUS PROSTATIC URETHRAL LIFT:ASSESSMENT AND COMPARISON OF THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA No dispute reported 06/30/2026 1242470510
Principal investigator 1 Teleflex Medical Incorporated $29.70 01/06/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
INVESTIGATING MEDICATION VERSUS PROSTATIC URETHRAL LIFT:ASSESSMENT AND COMPARISON OF THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA No dispute reported 06/30/2026 1242470512
Principal investigator 1 Teleflex Medical Incorporated $135.00 01/06/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
INVESTIGATING MEDICATION VERSUS PROSTATIC URETHRAL LIFT:ASSESSMENT AND COMPARISON OF THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA No dispute reported 06/30/2026 1242470514
Principal investigator 1 Teleflex Medical Incorporated $5,373.66 01/06/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
INVESTIGATING MEDICATION VERSUS PROSTATIC URETHRAL LIFT:ASSESSMENT AND COMPARISON OF THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA No dispute reported 06/30/2026 1242470516
Principal investigator 1 Teleflex Medical Incorporated $1,997.50 01/06/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
INVESTIGATING MEDICATION VERSUS PROSTATIC URETHRAL LIFT:ASSESSMENT AND COMPARISON OF THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA No dispute reported 06/30/2026 1242470518
Principal investigator 1 Teleflex Medical Incorporated $2,105.00 01/06/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
INVESTIGATING MEDICATION VERSUS PROSTATIC URETHRAL LIFT:ASSESSMENT AND COMPARISON OF THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA No dispute reported 06/30/2026 1242470520
Principal investigator 1 Teleflex Medical Incorporated $1,120.00 01/06/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
INVESTIGATING MEDICATION VERSUS PROSTATIC URETHRAL LIFT:ASSESSMENT AND COMPARISON OF THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA No dispute reported 06/30/2026 1242470522
Principal investigator 1 Teleflex Medical Incorporated $1,930.00 01/06/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
INVESTIGATING MEDICATION VERSUS PROSTATIC URETHRAL LIFT:ASSESSMENT AND COMPARISON OF THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA No dispute reported 06/30/2026 1242470524
Principal investigator 1 Janssen Research & Development, LLC $47,115.00 01/02/2025 Non-covered Recipient Entity
UROLOGY AUSTIN PLLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175335286